Trocar Site Incisional Hernia Prevention
Launched by HOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. · Jan 6, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to prevent incisional hernias, which are bulges that can occur at the site of surgical cuts, after laparoscopic surgery (a type of minimally invasive surgery). Specifically, the study will compare two methods of closing the umbilical trocar site (the small cut made for inserting instruments during surgery): one method uses a special mesh to reinforce the area, while the other uses a standard closure device. Participants will be adult patients scheduled for elective laparoscopic gallbladder removal surgery and will be randomly assigned to one of the two groups. An ultrasound will be done 12 months after surgery to check for any hernias that may have developed.
To be eligible for this trial, participants must be adults undergoing the surgery at the hospital, and they should be in good health (not classified as very ill by the American Society of Anesthesiologists). Unfortunately, those who have allergies to the mesh materials, existing hernias, or are undergoing emergency surgery won't be able to participate. This study is important because it aims to find better ways to reduce the risk of hernias after surgery, which can affect about 30% of patients. Participants can expect to receive follow-up care and monitoring to ensure their health and safety throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing elective laparoscopic cholecystectomy, with or without an exploration of the common bile duct, undergoing surgery in our hospital
- • ASA (American Society of Anesthesiologists) \<IV
- Exclusion Criteria:
- • Allergy or intolerance to any of the mesh components
- • Patients presenting already primary or incisional hernia of the abdominal wall
- • ASA ≥IV
- • Intraoperative conversion to laparotomy
- • Emergency surgery
- • Pregnancy
About Hospital Universitari Joan Xxiii De Tarragona.
Hospital Universitari Joan XXIII de Tarragona is a leading medical institution dedicated to providing advanced healthcare and fostering innovative research. As a prominent academic hospital affiliated with the Universitat Rovira i Virgili, it plays a pivotal role in clinical education and the development of new medical therapies. The hospital is committed to enhancing patient care through cutting-edge clinical trials, focusing on various therapeutic areas to improve health outcomes. With a multidisciplinary team of experienced professionals, Hospital Universitari Joan XXIII de Tarragona aims to contribute significantly to the advancement of medical science and the enhancement of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tarragona, , Spain
Valls, Tarragona, Spain
Patients applied
Trial Officials
Carles Olona Casas, MD
Study Director
Hospital Universitari de Tarragona
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials